Department of Surgery, Zhejiang Hospital, 12 Lingyin Road, Zhejiang, 310013, China.
Department of Health management, Sir Run Run Shaw International Medical Centre, 9 Jingtan Road, Hangzhou, 310000, Zhejiang, China.
World J Surg Oncol. 2024 Nov 20;22(1):306. doi: 10.1186/s12957-024-03595-z.
Digestive system cancers pose a significant global health challenge with high incidence and mortality rates. Inflammation is a key factor in cancer progression, necessitating reliable prognostic indicators. The pan-immune-inflammation value (PIV), as a new biomarker of immune-inflammatory response, has emerged as a potential prognostic biomarker for cancers.
We performed a meta-analysis to evaluate the prognostic significance of PIV in digestive system cancers. Our search, up to June 2024, included 20 studies from 19 articles with 5037 patients. We extracted and analyzed data on PIV levels and assessed hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS) using STATA 14.0.
Our analysis found that high PIV levels were significantly associated with poor prognosis in patients with digestive system cancers. Specifically, high PIV was linked to shorter OS (HR = 2.039, P < 0.001), PFS (HR = 1.877, P = 0.028), DFS (HR = 1.624, P = 0.005), RFS (HR = 2.393, P = 0.037), and CSS (HR = 2.053, P < 0.001). Additionally, the adverse prognostic impact of high PIV on OS was consistent across different cancer types, including digestive tract, colorectal, esophageal, and hepatobiliary pancreatic cancers. Although some heterogeneity was observed, sensitivity and bias analyses confirmed the reliability of these findings.
PIV was a valuable and practical prognostic marker for digestive system cancers, providing significant predictive value across multiple survival metrics. Its simplicity and minimal invasiveness nature support its potential integration into routine clinical practice.
消化系统癌症的发病率和死亡率都很高，是全球健康面临的重大挑战。炎症是癌症进展的一个关键因素，因此需要可靠的预后指标。作为一种新的免疫炎症反应的生物标志物，全免疫炎症值（PIV）已成为癌症潜在的预后生物标志物。
我们进行了荟萃分析，以评估 PIV 在消化系统癌症中的预后意义。我们的搜索截至 2024 年 6 月，包括来自 19 篇文章的 20 项研究，共有 5037 名患者。我们提取并分析了 PIV 水平的数据，并使用 STATA 14.0 评估了总生存期（OS）、无进展生存期（PFS）、无病生存期（DFS）、无复发生存期（RFS）和癌症特异性生存期（CSS）的风险比（HRs）。
我们的分析发现，高 PIV 水平与消化系统癌症患者的预后不良显著相关。具体而言，高 PIV 与较短的 OS（HR=2.039，P<0.001）、PFS（HR=1.877，P=0.028）、DFS（HR=1.624，P=0.005）、RFS（HR=2.393，P=0.037）和 CSS（HR=2.053，P<0.001）有关。此外，高 PIV 对 OS 的不良预后影响在不同的癌症类型中是一致的，包括消化道、结直肠癌、食管癌和肝胆胰腺癌症。尽管存在一些异质性，但敏感性和偏倚分析证实了这些发现的可靠性。
PIV 是一种有价值且实用的消化系统癌症预后标志物，在多个生存指标上具有显著的预测价值。其简单性和微创性使其有可能被纳入常规临床实践。
